CNBCLean R·
Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
Read at CNBC →
Business · 1 sources covering this
Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/7be5b6f0591d3211e7e786272431d464f80895be" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Cholesterol drug setback casts doubt over multibillion-dollar race"></iframe>
